A. Krause

发表

Visualization and Communication of Pharmacometric Models With Berkeley Madonna

A. Krause, P. Lowe, P J Lowe, 2014, CPT: pharmacometrics & systems pharmacology.

Qua titative assess e t of the effects of the selective S 1 P 1 receptor odulator

T. Lehr, J. Dingemanse, A. Krause, 2018 .

Confidence and Prediction Intervals for Pharmacometric Models

P. Bonate, A. Kümmel, J. Dingemanse, 2018, CPT: pharmacometrics & systems pharmacology.

Modeling the Effect of the Selective S1P1 Receptor Modulator Ponesimod on Subsets of Blood Lymphocytes

T. Lehr, J. Dingemanse, A. Krause, 2017, Pharmaceutical Research.

Modeling of pharmacokinetics, efficacy, and hemodynamic effects of macitentan in patients with pulmonary arterial hypertension.

J. Zisowsky, J. Dingemanse, A. Krause, 2018, Pulmonary pharmacology & therapeutics.

A New Reversible and Potent P2Y12 Receptor Antagonist (ACT-246475): Tolerability, Pharmacokinetics, and Pharmacodynamics in a First-in-Man Trial

J. Dingemanse, A. Krause, D. Baldoni, 2014, Clinical Drug Investigation.

Biomarker‐guided clinical development of the first‐in‐class anti‐inflammatory FPR2/ALX agonist ACT‐389949

A. Stalder, P. Groenen, J. Dingemanse, 2017, British journal of clinical pharmacology.

Pharmacokinetic/pharmacodynamic modelling of the antimalarial effect of Actelion‐451840 in an induced blood stage malaria study in healthy subjects

J. McCarthy, J. Möhrle, J. Dingemanse, 2016, British journal of clinical pharmacology.

Multiple‐dose tolerability, pharmacokinetics, and pharmacodynamics of ponesimod, an S1P1 receptor modulator: Favorable impact of dose up‐titration

H. Maatouk, A. Halabi, J. Dingemanse, 2014, Journal of clinical pharmacology.

Vancomycin-Lipopeptide Conjugates with High Antimicrobial Activity on Vancomycin-Resistant Enterococci

U. Haberkorn, K. Ohlsen, W. Mier, 2020, Pharmaceuticals.

Transition from Syringe to Autoinjector Based on Bridging Pharmacokinetics and Pharmacodynamics of the P2Y12 Receptor Antagonist Selatogrel in Healthy Subjects

Isabelle Zenklusen, J. Dingemanse, M. Ufer, 2021, Clinical Pharmacokinetics.

Influence of hepatic impairment on the pharmacokinetics and pharmacodynamics of the P2Y12 receptor antagonist selatogrel

A. Halabi, J. Dingemanse, A. Krause, 2022, Clinical and translational science.

Challenges in collecting pharmacokinetic and pharmacodynamic information in an intensive care setting: PK/PD modelling of clazosentan in patients with aneurysmal subarachnoid haemorrhage

J. Zisowsky, J. Dingemanse, A. Krause, 2014, European Journal of Clinical Pharmacology.

Concepts and Principles of Clinical Data Graphics

Andreas Krause, A. Krause, 2012 .

Pharmacokinetics of the novel oral prostacyclin receptor agonist selexipag in subjects with hepatic or renal impairment.

A. Halabi, J. Dingemanse, A. Krause, 2016, British journal of clinical pharmacology.

Target-Mediated Population Pharmacokinetic Modeling of Endothelin Receptor Antagonists

T. Lehr, J. Dingemanse, A. Krause, 2019, Pharmaceutical Research.

Pharmacokinetic/pharmacodynamic modeling of drug interactions at the P2Y12 receptor between selatogrel and oral P2Y12 antagonists

J. Dingemanse, A. Krause, A. Henrich, 2021, CPT: pharmacometrics & systems pharmacology.

Assessment of maximal tubular phosphate reabsorption: comparison of direct measurement with the nomogram of Bijvoet

A. Krause, P. Hoyer, J. Brodehl, 1988, Pediatric Nephrology.

Ensemble modeling highlights importance of understanding parasite-host behavior in preclinical antimalarial drug development

M. Penny, J. Möhrle, J. Dingemanse, 2020, Scientific Reports.

Strategies for the treatment of HBV/HDV

U. Haberkorn, W. Mier, A. Krause, 2018, European journal of pharmacology.

Pharmacokinetic/Pharmacodynamic Modelling of Receptor Internalization with CRTH2 Antagonists to Optimize Dose Selection

J. Zisowsky, P. Groenen, J. Dingemanse, 2016, Clinical Pharmacokinetics.

Pediatric Development of Bosentan Facilitated by Modeling and Simulation

J. Zisowsky, M. Beghetti, J. Dingemanse, 2017, Pediatric Drugs.

PK/PD modeling of a clazosentan thorough QT study with hysteresis in concentration-QT and RR-QT

J. Dingemanse, A. Krause, A. Henrich, 2021, Journal of pharmacokinetics and pharmacodynamics.

Mitigation of Initial Cardiodynamic Effects of the S1P1 Receptor Modulator Ponesimod Using a Novel Up‐Titration Regimen

J. Dingemanse, A. Krause, M. Hoch, 2017, Journal of clinical pharmacology.

Drug Development for Pediatric Populations: Regulatory Aspects

J. Zisowsky, J. Dingemanse, A. Krause, 2010, Pharmaceutics.

Target-Mediated Drug Disposition Pharmacokinetic–Pharmacodynamic Model of Bosentan and Endothelin-1

W. Haefeli, T. Lehr, J. Dingemanse, 2017, Clinical Pharmacokinetics.

Population Modeling of Selexipag Pharmacokinetics and Clinical Response Parameters in Patients With Pulmonary Arterial Hypertension

J. Dingemanse, A. Krause, M. Machacek, 2017, CPT: pharmacometrics & systems pharmacology.

PK/PD modeling of a clazosentan thorough QT study with hysteresis in concentration-QT and RR-QT

J. Dingemanse, A. Krause, A. Henrich, 2021, Journal of Pharmacokinetics and Pharmacodynamics.

Population pharmacokinetic modeling of daridorexant, a novel dual orexin receptor antagonist

J. Dingemanse, A. Krause, D. Lott, 2022, CPT: pharmacometrics & systems pharmacology.

Estimation of Attainment of Steady‐State Conditions for Compounds With a Long Half‐Life

J. Dingemanse, A. Krause, D. Lott, 2020, Journal of clinical pharmacology.

Pharmacometrics: The Science of Quantitative Pharmacology

A. Krause, Andreas Krause, 2008 .

Impact of pharmacokinetic‐pharmacodynamic modelling in early clinical drug development

J. Dingemanse, A. Krause, 2017, European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.

Visualization Concepts to Enhance Quantitative Decision Making in Drug Development

Richard Pugh, Kevin Dykstra, Andreas Krause, 2010, Journal of clinical pharmacology.

Statistics and the Drug Development Process

Steven P. Millard, Andreas Krause, Bruce Rodda, 2001 .

A Picture is Worth a Thousand Tables

Andreas Krause, Michael O'Connell, A. Krause, 2012, Springer US.

Modeling and Simulation of Pivotal Clinical Trials Using Linked Models for Multiple Endpoints in Chronic Obstructive Pulmonary Disease With Roflumilast

R. Bruno, A. Facius, A. Krause, 2017, Journal of clinical pharmacology.

Ensemble modeling highlights importance of understanding parasite-host behavior in preclinical antimalarial drug development

M. Penny, J. Möhrle, J. Dingemanse, 2020, Scientific Reports.

Interactive Visualization and Communication for Increased Impact of Pharmacometrics

Andreas Krause, Ronald Gieschke, R. Gieschke, 2010, Journal of clinical pharmacology.

Tolerability and Pharmacokinetics of ACT-280778, a Novel Nondihydropyridine Dual L/T-type Calcium Channel Blocker: Early Clinical Studies in Healthy Male Subjects Using Adaptive Designs

Markus S. Mueller, B. Sanderson, J. Dingemanse, 2014, Journal of cardiovascular pharmacology.

Integrated pharmacokinetics and pharmacodynamics of epoprostenol in healthy subjects.

J. Dingemanse, A. Krause, L. Nicolas, 2012, British journal of clinical pharmacology.

Impact of Daridorexant, a Dual Orexin Receptor Antagonist, on Cardiac Repolarization Following Bedtime Dosing: Results from a Thorough QT Study Using Concentration-QT Analysis

J. Dingemanse, M. Ufer, A. Krause, 2021, Clinical Drug Investigation.

Modeling Tolerance Development for the Effect on Heart Rate of the Selective S1P1 Receptor Modulator Ponesimod

T. Lehr, J. Dingemanse, A. Krause, 2018, Clinical pharmacology and therapeutics.

Impact of Demographics, Organ Impairment, Disease, Formulation, and Food on the Pharmacokinetics of the Selective S1P1 Receptor Modulator Ponesimod Based on 13 Clinical Studies

T. Lehr, J. Dingemanse, A. Krause, 2017, Clinical Pharmacokinetics.

Population pharmacokinetics and pharmacodynamics of ponesimod, a selective S1P1 receptor modulator

D. d'Ambrosio, J. Dingemanse, A. Krause, 2014, Journal of Pharmacokinetics and Pharmacodynamics.

Population pharmacokinetics of ponesimod and its primary metabolites in healthy and organ-impaired subjects.

T. Lehr, J. Dingemanse, A. Krause, 2016, European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.

Modelling pharmacokinetics and pharmacodynamics of the selective S1P1 receptor modulator cenerimod in healthy subjects and systemic lupus erythematosus patients

J. Dingemanse, A. Krause, D. Lott, 2019, British journal of clinical pharmacology.

Modeling clinical efficacy of the S1P receptor modulator ponesimod in psoriasis.

D. d'Ambrosio, J. Dingemanse, A. Krause, 2017, Journal of dermatological science.

Applied statistics in the pharmaceutical industry : with case studies using S-Plus

Steven P. Millard, Andreas Krause, S. Millard, 2001 .

Ultrafiltration profiling and measurement of relative blood volume as strategies to reduce hemodialysis-related side effects.

J. Donauer, A. Krause, M. Bek, 2000, American journal of kidney diseases : the official journal of the National Kidney Foundation.

The Case for an Unblinded Modeler in Early Clinical Development

Andreas Krause, Andrea Henrich, Jasper Dingemanse, 2020, Journal of clinical pharmacology.

Applied Statistics in the Pharmaceutical Industry

Steven P. Millard, Andreas Krause, S. Millard, 2010 .

Training the next generation of pharmacometric modelers: a multisector perspective.

P. Bonate, B. Corrigan, M. Neely, 2023, Journal of pharmacokinetics and pharmacodynamics.

Modeling time‐delayed concentration‐QT effects with ACT‐1014‐6470, a novel oral complement factor 5a receptor 1 (C5a1 receptor) antagonist

J. N. van den Anker, M. Pfister, J. Dingemanse, 2023, Pharmacology research & perspectives.

Modeling and Simulation to Adjust p Values in Presence of a Regression to the Mean Effect

A. Krause, Andreas Krause, José Pinheiro, 2007 .